Aims: The aim of study was to evaluate glucose control in obese diabetics during six months of treatment with glargin insulin in combination with metformin and glimepirid.
Methods: In beginning of study excluded patients who had coronary heart and kidneys disease before. In study included 43 obese diabetics with type 2 diabetes [23 male and 20 female, BMI=29.82±1.91 kg/m2, aged 4265 yr], who had previously been treated with different orally antidiabetics. Previous treatment was without results, because all treated patients had bed glicoregulation. Patients divided in two groups. Both groups were without significant difference in BMI, age and sex. Twenty five patients (14 male and 11 female) received glargin s.c. once a day and metformin orally at the dose of 3×850 mg/d. Eighteen diabetics (10 male and 8 female) received glargin s.c. once a day and glimepirid orally at the dose of 24 mg/d. Glicoregulation evaluated by measuring fast blood glucose (FBG), postprandial blood glucose (PBG) and HbA1c. Duration of study was six months. Percentile, average and correlation analysis have been utilized in statistical analysis.
Results: The results of study, after six months treatment with glargin and metformin, show statistical significantly decreasing of FBG (6,7+/−1.4 mmol/l, vs 9.9+/−2.9 mmol/l, P<0.05), PBG and HbA1c (7.0+/−1.3% vs 9.1+/−1.3%, P<0.05). BMI decreased for 10% (27.1+/−0.9 kg/m2 vs 29.82±1.91 kg/m2). In group treated with glargin and glimepirid FBG, PBG and HbA1c (7.7+/−1.2% vs 9.3+/−1.1%, P<0.05) as well decreased but no more then group treated with glargin and metformin.
Conclusion: Glargin in combination with metformin is more effective in treatment of obese diabetics then glargin in combination with glimepirid.